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Abstract
Introduction: Rheumatoid arthritis (RA) is characterized by synovial lining hyperplasia, in which there may be an
imbalance between the growth and death of fibroblast-like synoviocytes (FLSs). Antibodies against citrullinated
proteins are proposed to induce RA. This study aimed to investigate the pathogenic role of citrullinated fibronectin
(cFn) in RA.
Methods: The distribution of fibronectin (Fn) and cFn in synovial tissues from RA and osteoarthritis (OA) patients
was examined by immunohistochemical and double immunofluorescence analysis. FLSs were isolated from RA and
OA patients and treated with Fn or cFn. Apoptosis was detected by flow cytometry and TUNEL assay. The
expression of survivin, caspase-3, cyclin-B1, Bcl-2 and Bax was detected by real-time PCR. The secretion of
proinflammatory cytokines was measured by ELISA.
Results: Fn formed extracellular aggregates that were specifically citrullinated in synovial tissues of RA patients, but
no Fn deposits were observed in those of OA patients. Fn induced the apoptosis of RA and OA FLSs while cFn
inhibited the apoptosis of RA and OA FLSs. Fn significantly increased the expression of caspase-3 and decreased
the expression of survivin and cyclin-B1 in FLSs from RA and OA patients. cFn significantly increased the expression
of survivin in RA FLSs. Furthermore, cFn increased the secretion of TNF-a and IL-1 by FLSs.
Conclusions: cFn plays a potential pathophysiologic role in RA by inhibiting apoptosis and increasing
proinflammatory cytokine secretion of FLSs.
Introduction
Rheumatoid arthritis (RA) is a chronic systemic autoim-
mune disease characterized by persistent inflammation
of the synovial tissues of the joints, resulting in the loss
of joint function, morbidity and premature mortality.
Fibroblast-like synoviocytes (FLSs) play important role
in the initiation and perpetuation of RA [1]. FLSs are
characterized by the resistance to apoptosis and the con-
sequent overexpansion and destruction of articular
cartilage.
Anti-cyclic citrullinated protein (anti-CCP) antibodies
belong to the family of anti-fillagrin autoantibodies [2].
Anti-CCP antibodies are produced locally in the syno-
vium of RA patients [3]. These antibodies specifically
recognize the proteins containing citrulline amino acid
residues, which is generated via post-translational modi-
fication of arginine residues by peptidylarginine deimi-
nase (PADI) [4,5]. Arginine residues often play a central
role in the structural integrity of a protein, due to their
ability to participate in ionic interactions with negatively
charged amino acid side chains, substrates, and cofac-
tors, and form multiple hydrogen bonds to the peptide
backbone and other amino acid side chains [6]. Citrulli-
nation could destroy the ionic interactions, interfere
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with hydrogen bonds, and create new interactions.
Therefore, the conversion of arginine into citrulline may
lead to the changes in protein structure and function.
Notably, the citrullinated forms of fibrinogen, fibronec-
tin (Fn), fibrin, vimentin, collagen type II and a-enolase
are common in the inflamed synovium and citrullinated
fibrinogen, citrullinated fibronectin (cFn), citrullinated
fibrin and citrullinated vimentin in the inflamed syno-
vium and plasma have been considered as important
citrullinated autoantigens in RA [4,7-12].
Fn comprises a large family of isomeric glycoproteins
characterized by repeated amino acid units that form
domains. These domains interact with various compo-
nents of extracellular matrix (ECM), integrin and growth
factors, which play critical roles in various physiological
processes, including cell adhesion, migration, prolifera-
tion, differentiation, wound healing, fibrosis and hemos-
tasis [13]. Fn has been shown to be synthesized locally
by FLSs [14]. High level of Fn in the synovial fluid was
positively correlated with the progression of joint
destruction [15,16]. In addition, significant amount of
cFn was present in RA synovial tissue where they
formed extracellular aggregates [11].
To further elucidate the pathogenic roles of the citrul-
linated autoantigens, in the present study we isolated
FLSs from the synovial tissues obtained from RA and
osteoarthritis (OA) patients and exposed them to cFn or
Fn. The results showed that cFn inhibited the apoptosis
and promoted the secretion of proinflammatory cyto-
kines in FLSs from RA patients, suggesting the patho-
genic role of cFn in RA.
Materials and methods
Patients and controls
Synovial tissues were obtained from eight RA patients
(two males, six females, median age 58 years, range 48
to 74 years) and six OA patients (three males, three
females, median age 60 years, range 48 to 77 years) who
underwent knee arthroscopic or replacement surgery.
The tissue samples were immediately put into 1640
medium and processed within 4 h for FLSs culture and
histological and immunohistochemical analysis. All
patients fulfilled the American College of Rheumatology
(ACR) criteria for the diagnosis of RA and OA.
Informed consent was obtained from all patients and
the study protocol was approved by Ethics Committee
of Shanghai East Hospital.
Isolation and culture of FLSs
Synovial tissues were minced into pieces of 2 to 3 mm
in size and spread on the bottom of cell culture flasks in
1640 medium at 37°C for 6 h. Next, the tissues were
incubated with complete 1640 medium supplemented
with 10% fetal calf serum in a humidified atmosphere
containing 5% CO2. The medium was changed every
three to five days and non-adherent tissue pieces were
carefully removed. FLSs were grown further over four to
six passages. To characterize the cytological phenotype
of synovial cultures, the third passage cells were stained
with mouse mAb against human CD14 and CD90
(eBioscience, San Diego, CA, USA) and showed 2.8%
CD14 and 97.0% CD90 expression as measured by flow
cytometry.
In vitro citrullination of Fn
Native human plasma Fn (Sigma-Aldrich, St Louis, MO,
USA) at a final concentration of 0.5 mg/ml was incu-
bated with 5 units/ml of PADI from rabbit skeletal mus-
cle (Sigma-Aldrich, St Louis, MO, USA) in working
buffer (100 mM Tris-HCl, 5 mM CaCl2, pH 7.4) at 37°C
for 24 h. The reaction was stopped by the addition of
20 mM EDTA. The citrullination of Fn was detected by
Western blot analysis with antibody against modified
citrulline residues (anti-MC, Abcam, Cambridge, MA,
USA).
Immunohistochemical and immunofluorescence analysis
Synovial tissue samples were paraffin-embedded and cut
into 5 μm sections. Sections were deparaffinized and
rehydrated using standard procedures, and were stained
with hematoxylin and eosin (H & E). The sections were
incubated with mouse monoclonal antibody against
human Fn (1:1000, Abcam, Cambridge, MA, USA) or
rabbit polyclonal antibody against modified citrulline
residues (anti-MC, 1:500, Abcam, Cambridge, MA,
USA) at 4°C overnight. Next the sections were incu-
bated with second antibody (EnVision™ Detection Kit,
Dako, Glostrup, Denmark) for 30 min at room tempera-
ture. Immunoreactive signals were visualized using
DAB. For double immunofluorescence staining, the sec-
tions were incubated with Fn antibody or anti-MC anti-
body at 4°C overnight, then incubated with anti-rabbit
immunoglobulin G (IgG) fluorescein isothiocyanate
(FITC) (1:50, eBioscience, San Diego, CA, USA). and
anti-mouse IgG PE (1:100, eBioscience, San Diego, CA,
USA) at 37°C for 30 min. After rinsing with PBS, the
sections were observed under fluorescence microscope.
Flow cytometry analysis of apoptosis
FLSs were stained with FITC-conjugated annexin V and
propidium iodide (PI). FLSs were seeded in 24 well
plates at 1 × 105 cells/well in 500 μl media and treated
with 2 μg/ml Fn or cFn at 37°C for 72 h. Next, FLSs
were trypsinized and collected for the detection of apop-
tosis by using Annexin V-FITC Apoptosis Detection Kit
(eBioscience, San Diego, CA, USA). Briefly, FLSs were
washed twice with cold PBS and resuspended in 500 μL
binding buffer (10 mM HEPES-NaOH pH 7.4, 140 mM
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NaCl, 2.5 mM CaCl2) at a concentration of 1 × 10
6
cells/ml. After the addition of 5 μl Annexin V-FITC
solution and PI (1 μg/ml), the cells were incubated for
15 min at room temperature and then analyzed by flow
cytometer (Beckman Coulter, Fullerton, CA, USA).
TUNEL assay
FLSs were seeded in six-well plates containing coverslips
at 2 × 105 cells/well and treated with Fn or cFn (2 μg/
ml) for 48 h. Apoptotic cells were detected by using In
Situ Cell Death Detection Kit according to the manufac-
turer’s instructions. Briefly, the cells were fixed with 4%
paraformaldehyde for 1 h at room temperature and per-
meabilized with 0.1% Triton X-100. Next the cells were
incubated with terminal deoxyribonucleotidyl transferase
mediated dUTP nick-end labeling (TUNEL) reaction
mixture for 1 hr at 37°C in the dark. For positive con-
trols, the cells were incubated with DNase I (grade I; 3
to 3,000 U/ml in 50 mM Tris-HCl pH 7.5, 1 mg/ml
BSA) for 10 min at 15 to 25°C to induce DNA strand
breaks before labeling procedures. For negative controls,
terminal transferase was omitted from the reaction mix-
ture. All samples were directly analyzed under fluores-
cence microscope.
ELISA
Human TNF-a, IL-1 and IL-17 levels were measured in
the supernatant of FLSs using commercially available
kits (R&D systems, Minneapolis, MN, USA) according
to the manufacturer’s instructions. The optical density
(OD) of the samples was read using a microplate reader
(Bio-Rad, Hercules, CA, USA) at a wavelength of 450
nm. A standard curve was generated using the OD
values of standard solution for TNF-a, IL-1 and IL-17
concentration estimation.
Quantitative RT-PCR analysis
Total RNA was extracted from FLSs using TRIzol (Invi-
trogen, Carlsbad, CA, USA) and reverse transcription
was performed using first strand cDNA Synthesis Kit
(Takara, Dalian, China) according to the manufacturer’s
instructions. Real-time PCR was performed using Pre-
mix Ex Taq SYBR Green PCR (Takara, Dalian, China)
according to the manufacturer’s instructions on an ABI
PRISM 7300 (Applied Biosystems, Foster City, CA,














CACCCA 3’, 5’ -CACCCTGTTGCTGTAGCCAAA -3’.
b-actin was used as internal control.
Western blot analysis
Whole cell lysates were prepared from about 2 × 105 cells
by homogenization in the lysis buffer and subsequent cen-
trifugation at 14,000 rpm for 15 min. The protein concen-
tration in the supernatant was determined using the
Bradford method (Bio-Rad, Hercules, CA, USA). Protein
samples were separated on 10% SDS-PAGE and then
transferred onto nitrocellulose membranes (Amersham
Pharmacia Biotech, Uppsala, Sweden). The membranes
were incubated with primary antibody such as anti-MC
Ab, (Abcam, Cambridge, MA, USA), anti-PADI4 (Abcam,
Cambridge, MA, USA) or anti-receptor activator of
nuclear factor kappa B ligand (RANKL) (Santa Cruz Bio-
technology Inc., Santa Cruz, California, USA), then incu-
bated with horseradish peroxidase-conjugated secondary
antibody. All immunoreactive proteins were visualized
with SuperSignals west Pico Chemiluminescent Substrate
(Thermo Scientific, Rockford, IL, USA).
Statistical analysis
The differences between means were evaluated using
multiple related samples Friedman M test. Where
appropriate, further pairwise comparisons were analyzed
using multiple related samples q test. SPSS16.0 program
package (SPSS Inc., Chicago, IL, USA) was used for all
statistical analyses. A P value of 0.05 or less than was
considered statistically significant.
Results
cFn is abundant in arthritic synovial tissues
To clarify the distribution of cFn in synovial tissues
from RA and OA, we performed immunostaining and
double immunofluorescent staining. Fn immunostaining
was mainly detected at the outer surface of the RA
synovial membrane where Fn formed a tight block but
not synoviocytes (Figure 1A). Notably, the majority of
such extracellular masses was also immunopositive by
anti-MC staining, indicating that Fn was citrullinated.
The results of double immunofluorescent staining
showed similar patterns (Figure 1B). In contrast, extra-
cellular accumulation of Fn and citrullination of proteins
were undetectable in OA synovial tissue except for the
deep subling region where some fibrous materials and
endothelial cells were immunostained by anti-MC anti-
body. These results demonstrate that cFn is abundant in
arthritic synovial tissues.
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Figure 1 The distribution of Fn and citrullinated proteins in arthritic synovial tissues from RA and OA patients. (A)
Immunohistochemistry staining. Continuous sections of RA or OA synovial tissues were probed with ant-Fn Ab and anti-MC Ab, respectively. For
negative controls, primary Ab was replaced by normal serum. Original magnification: x200. (B) Double immunofluorescent staining. The sections
of RA or OA synovial tissues were probed with anti-Fn Ab and anti-MC Ab, followed by incubation with second antibody anti-rabbit IgG FITC
(green) or anti-mouse IgG PE (red). Original magnification: x200. anti-MC Ab, criteria anticitrulline (modified) antibody; FITC, fluorescein
isothiocyanate; Fn, fibronectin; IgG, immunoglobulin G; OA, osteoarthritis; RA, rheumatoid arthritis.
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Fn and cFn modulates the apoptosis of FLSs
To evaluate the pathological significance of cFn accu-
mulation for RA progression, we isolated FLSs from RA
and OA patients as the experimental model. We pre-
pared cFn and citrullinated BSA (cBSA) by in vitro
citrullination using Fn and BSA as substrates, respec-
tively. Western blot analysis with anti-MC antibody con-
firmed the citrullination of Fn and BSA (data not
shown). Next, we treated FLSs with Fn and cFn and
then detected the apoptosis of FLSs by Annexin V-
FITC/PI staining and TUNEL assay. As controls we
treated FLSs with BSA, cBSA or PADI and observed
that BSA, cBSA or PADI had no significant effect on
the apoptosis of FLSs isolated from RA or OA (Figure
2). Fn significantly increased the apoptosis of FLSs iso-
lated from RA and OA (Annexin V-FITC/PI, P < 0.05;
TUNEL P < 0.01). However, cFn attenuated the apopto-
sis of FLSs isolated from RA and OA (Figure 2).
To further elucidate the molecular mechanisms of Fn-
induced apoptosis of FLSs, we examined the effects of
Fn and cFn on the expression of apoptosis-related mole-
cules. Fn significantly decreased the expression of survi-
vin and cyclin-B1, but increased the expression of
caspase 3 in FLSs from RA and OA (P < 0.05, Figure 3).
In contrast, cFn significantly increased the expression of
survivin in FLSs isolated from RA (P < 0.01). The
expression of both Bcl-2 and Bax was not different in
FLSs treated by 2 μg/ml Fn or cFn compared with trea-
ted control FLSs. These results suggest that survivin is
implicated in Fn-induced apoptosis of FLS.
Fn and cFn modulates the secretion of cytokines by FLSs
We next investigated whether Fn and cFn have effects
on the secretion of cytokines by FLSs isolated from RA
or OA patients. ELISA assay showed that cFn increased
the secretion of TNF-a and IL-1 by RA FLSs while Fn
had no obvious effects on the secretion of TNF-a and
IL-1 by RA FLSs. For OA FLSs, TNF-a secretion did
not show any difference after Fn or cFn treatment (Fig-
ure 4). In addition, the secretion of IL-17 by RA and
OA FLSs did not show any difference after Fn or cFn
treatment (Figure 4). As the controls, we observed that
BSA, cBSA, PADI had no significant effects on the
secretion of TNF-a, IL-1 and IL-17 by FLSs (data not
shown). Collectively, these results suggest that Fn and
cFn exhibit specific effects on the secretion of TNF-a
and IL-1 by FLSs isolated from RA patients.
Fn and cFn have no effects on the expression of PADI4
and RANKL in FLSs
We assessed the expression of PADI4 and RANKL in
FLSs and to further investigate the effects of Fn or cFn
on the mRNA expression and protein levels of the
PADI4 and RANKL in RA and OA FLSs. RT-PCR and
Western blot analysis showed that Fn and cFn had no
significant effects on the expression of PADI4 and
RANKL at mRNA and protein levels in FLSs (Figure 5).
Discussion
It is generally accepted that citrullinated proteins/pep-
tides could evoke immune response leading to autoanti-
bodies against these peptides or proteins, so called anti-
cyclic citrullinated peptides (anti-CCP) [17]. The citrulli-
nated proteins/peptides and anti-CCP are implicated in
the development of RA in at least 70% patients [18].
However, current knowledge on the direct effects of
citrullinated proteins on the initiation and progression
in RA is extremely limited.
In this study, for the first time to our knowledge, we
demonstrated that cFn inhibited the apoptosis of FLSs
and augmented the secretion of proinflammatory cyto-
kines by FLSs. These effects may explain the pathogeni-
city of cFn in RA. In addition, as shown in the present
study, abundant Fn was mainly detected at the outer
surface of the RA synovial membrane where Fn formed
a tight block extracellularly. The majority of such extra-
cellular masses were also immunopositive by anti-MC
staining, indicating the abundant citrullination of Fn.
RA is a common chronic arthropathy characterized
by synovial hyperplasia and progressive joint destruc-
tion. The synovial tissue is mainly composed of FLSs,
which are key players in the physiopathology of RA
through the local secretion of proinflammatory cyto-
kines, inflammation mediators and proteolytic enzymes
that degrade EMC and destroy the joint structure. FLSs
derived from RA synovium exhibit aggressive and inva-
sive properties. It has been shown that the proliferation
rate of FLSs was similar whether they were isolated
from healthy individuals, RA or OA patients [19,20].
Thus the overgrowth of FLSs population in RA is more
likely due to an imbalance between cell proliferation,
survival, and death. In this study we proved that cFn
could inhibit the apoptosis of FLSs, which may pro-
mote their survival and participation in the pathogenic
process.
Apoptosis is tightly regulated by anti- or pro-apoptotic
molecules. Survivin is an important inhibitor of apopto-
sis that is undetectable in terminally differentiated adult
tissues but overexpressed in cancer [21,22]. In the pre-
sent study, we showed that Fn significantly inhibited the
expression of survivin and cyclin-B1, and promoted the
expression of caspase 3 in FLSs. However, cFn signifi-
cantly increased the expression of survivin in FLSs iso-
lated from RA patients. Meanwhile, the expression of
anti-apoptotic molecule Bcl-2 and pro-apoptotic mole-
cule Bax did not changed in FLSs treated by Fn or cFn.
These results demonstrate that the molecular
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Figure 2 The effects of Fn and cFn on the apoptosis of FLSs isolated from RA or OA patients. The isolated FLSs from RA and OA patients
were treated for 72 h as indicated and the apoptosis was detected by Annexin V-FITC/PI (A) and TUNEL analysis (B). RA (n = 8) and OA (n = 6)
* P < 0.05, ** P < 0.01, and NS, not significant. cFn, citrullinated fibronectin; FITC, fluorescein isothiocyanate; FLSs, fibroblast-like synoviocytes; Fn,
fibronectin; OA, osteoarthritis; PI, propidium iodide; RA, rheumatoid arthritis; TUNEL, terminal deoxyribonucleotidyl transferase mediated dUTP
nick-end labeling.
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mechanisms underlying Fn/cFn-regulated apoptosis are
due to survivin-dependent signal pathway. Additionally,
these data are consistent with previous study reporting
that the ability of Fn to promote the apoptosis of mono-
cytes was considerably reduced after citrullination [11].
Therefore, citrullination could change the function of
Fn and citrullinated autoantigens may play an important
role in the promotion of rheumatoid synovial hyperpla-
sia via the inhibition of FLSs apoptosis.
Various cytokines are known to play key roles as med-
iators of RA progression. In particular, TNF-a and IL-1
are located at the upstream of the cytokine cascade, and
are pivotal mediators in the induction of an excessive
reaction in vivo [23]. TNF-a appears to play important
role in triggering events leading to inflammation both
locally and systemically, whereas IL-1 is involved in car-
tilage and bone destruction [24]. In the present study
we demonstrated, for the first time, that cFn promoted
the secretion of TNF-a and IL-1 by FLSs from RA. This
further expands the importance of the pathophysiologic
role of the citrullinated autoantigens in RA.
Receptor activator of nuclear factor kappa B (RANK)
and its ligand, RANKL, are members of the TNF recep-
tor and TNF superfamilies, respectively. The RANKL/
Figure 3 The effects of Fn and cFn on the expression of apoptosis-related molecules in FLSs isolated from RA or OA patients. RA or
OA FLSs were treated with Fn or cFn at 2 μg/ml for 72 h and total RNA was isolated for the analysis of survivin, caspase 3, cyclin-B1, Bcl-2 and
Bax mRNA levels. RA (n = 8) and OA (n = 6). * P < 0.05 compared with blank, ** P < 0.01 compared with blank. Δ P < 0.05 compared with cFn,
ΔΔ P < 0.01 compared with cFn. cFn, citrullinated fibronectin; FLSs, fibroblast-like synoviocytes; Fn, fibronectin; OA, osteoarthritis; RA, rheumatoid
arthritis.
Figure 4 The effects of Fn and cFn on the secretion of TNF-a, IL-1 and IL-17 by FLSs isolated from RA or OA patients. RA or OA FLSs
were treated with Fn or cFn at 2 μg/ml for 72 h and the supernatants were collected for the analysis of TNF-a, IL-1 and IL-17 levels. RA (n = 8)
and OA (n = 6) * P < 0.05, ** P < 0.01, and NS, not significant. cFn, citrullinated fibronectin; FLSs, fibroblast-like synoviocytes; Fn, fibronectin; IL,
interleukin; OA, osteoarthritis; RA, rheumatoid arthritis; TNF-a, tumor necrosis factor alpha.
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RANK system is essential for osteoclast formation
[25,26]. The level of soluble RANKL was elevated in
synovial fluid of RA patients and both activated T cells
and FLSs express RANKL [27,28]. Page et al. reported
that treatment of synoviocytes with TNF-a or IL-1b in
combination with IL-17 is particularly potent for indu-
cing RANKL expression [29]. In the present study, we
found that treatment with cFn or native Fn did not
induce significant change in RANKL expression level in
RA and OA FLSs. These observations suggest that
RANKL is unlikely to be responsible for the inhibiton of
apoptosis and the overproduction of proinflammatory
cytokines in RA FLSs treated by cFn.
PADI mediates the post-translational deimination of
arginyl residues, a process named as citrullination. Several
studies reported that PADI4 was extensively expressed in
FLSs in the lining and sublining areas of RA synovium
that was responsible for the citrullination of fibrin
[30,31]. Interestingly, our recent results showed that
citrullinated vimentin could promote the expression of
PADI4 in FLSs [32], suggesting the possible existence of
a positive feedback loop that augments the citrullination
of proteins involved in RA. To investigate whether cFn
could also promote PADI4 expression in FLSs, we treated
FLSs with cFn and found that cFn and Fn had no signifi-
cant effects on PADI4 expression in FLSs. These results
suggest that the abundance of PADI4 in RA synovial tis-
sue may be mediated by other mechanisms than cFn.
Conclusions
Our present study demonstrated that cFn plays a poten-
tial pathophysiologic role in RA by inhibiting apoptosis
and increasing proinflammatory cytokine secretion of
FLSs. Insufficient apoptosis and/or enhanced proinflam-
matory cytokine production may contribute to the
increased number of FLSs and rheumatoid synovial
hyperplasia in RA joints. These findings provide new
insights into the role of citrullinated autoantigens in RA.
Further studies are necessary to elucidate the molecular
mechanism by which citrullinated proteins contribute to
the onset and progression of RA.
Abbreviations
ACR: American College of Rheumatology; anti-CCP: anti-cyclic citrullinated
protein antibodies; anti-MC Ab: criteria anticitrulline (modified) antibody;
BSA: bovine serum albumin; cFn: citrullinated fibronectin; ECM: extracellular
matrix; ELISA: enzyme-linked immunosorbent assay; FITC: fluorescein
isothiocyanate; FLSs: fibroblast-like synoviocytes; Fn: fibronectin; IgG:
immunoglobulin G; IL: interleukin; mAb: monoclonal antibody: OA:
osteoarthritis; PADI4: peptidylarginine deiminase type 4; PBS: phosphate-
buffered saline; PI: propidium iodide; RA: rheumatoid arthritis; RANKL:
receptor activator of nuclear factor kappa B ligand; RT-PCR: reverse
transcriptase polymerase chain reaction; SDS-PAGE: sodium dodecyl sulphate
polyacrylamide gel electrophoresis; TNF-α: tumor necrosis factor alpha;
TUNEL: terminal deoxyribonucleotidyl transferase mediated dUTP nick-end
labeling.
Acknowledgements
The study was supported by grants from the Shanghai Municipal Science
and Technology Commission for International Cooperation (No.
09410705000) and the National Natural Science Foundation of China (No.
81072467). We thank the patients for their contribution to this study and
thank all the members of the laboratory for stimulating discussion.
Author details
1Department of Clinical Laboratory, Shanghai East Hospital, School of
Medicine, Tong Ji University, 150 Ji Mo Road, Shanghai 200120, PR China.
2Department of General Surgery, Shanghai Zhabei District Central Hospital,
619 Zhong Hua Xin Road, Shanghai 200072, PR China. 3Department of
Rheumatology, General Hospital, Ningxia Medical University, 804 Shengli
South Road, Yinchuan 750004, PR China. 4Department of Rheumatology,
Figure 5 The effects of Fn and cFn on the expression of PADI4 and RANKL in FLSs isolated from RA or OA patients. RA or OA FLSs
were treated with Fn or cFn at 2 μg/ml for 72 h, the relative mRNA levels of PADI4 and RANKL were detected by RT-PCR (upper panels), and
the protein level of PADI4 and RANKL were detected by Western blot analysis (lower panels). RA (n = 8) and OA (n = 6). cFn, citrullinated
fibronectin; FLSs, fibroblast-like synoviocytes; Fn, fibronectin; OA, osteoarthritis; PADI4, peptidylarginine deiminase type 4; RA, rheumatoid arthritis;
RANKL, receptor activator of nuclear factor kappa B ligand; RT-PCR, reverse transcriptase polymerase chain reaction.
Fan et al. Arthritis Research & Therapy 2012, 14:R266
http://arthritis-research.com/content/14/6/R266
Page 8 of 9
Guanghua Hospital of Integrative Medicine, 540 Xin Hua Road, Shanghai
200052, PR China.
Authors’ contributions
LYF and QW designed and directed the research and drafted the
manuscript. RQL and DYH collected clinical samples and data. MZ, HZ, YYD
and JWM performed the experiments. All authors read and approved the
final manuscript for publication.
Competing interests
The authors have declared no conflicts of interest.
Received: 18 August 2012 Revised: 22 November 2012
Accepted: 6 December 2012 Published: 10 December 2012
References
1. Huber LC, Distler O, Tarner I, Gay RE, Gay S, Pap T: Synovial fibroblasts: key
players in rheumatoid arthritis. Rheumatology (Oxford) 2006, 45:669-675.
2. Sebbag M, Simon M, Vincent C, Masson-Bessière C, Girbal E, Durieux JJ,
Serre G: The antiperinuclear factor and the so-called antikeratin
antibodies are the same rheumatoid arthritis-specific autoantibodies. J
Clin Invest 1995, 95:2672-2679.
3. Baeten D, Peene I, Union A, Meheus L, Sebbag M, Serre G, Veys EM, De
Keyser F: Specific presence of intracellular citrullinated proteins in
rheumatoid arthritis synovium: relevance to antifilaggrin autoantibodies.
Arthritis Rheum 2001, 44:2255-2262.
4. Vossenaar ER, Zendman AJ, van Venrooij WJ, Pruijn GJ: PAD, a growing
family of citrullinating enzymes: genes, features and involvement in
disease. Bioessays 2003, 25:1106-1118.
5. Suzuki A, Yamada R, Chang X, Tokuhiro S, Sawada T, Suzuki M, Nagasaki M,
Nakayama-Hamada M, Kawaida R, Ono M, Ohtsuki M, Furukawa H,
Yoshino S, Yukioka M, Tohma S, Matsubara T, Wakitani S, Teshima R,
Nishioka Y, Sekine A, Iida A, Takahashi A, Tsunoda T, Nakamura Y,
Yamamoto K: Functional haplotypes of PADI4, encoding citrullinating
enzyme peptidylarginine deiminase 4, are associated with rheumatoid
arthritis. Nat Genet 2003, 34:395-402.
6. Borders CL Jr, Broadwater JA, Bekeny PA, Salmon JE, Lee AS, Eldridge AM,
Pett VB: A structural role for arginine in proteins: multiple hydrogen
bonds to backbone carbonyl oxygens. Protein Sci 1994, 3:541-548.
7. Masson-Bessière C, Sebbag M, Girbal-Neuhauser E, Nogueira L, Vincent C,
Senshu T, Serre G: The major synovial targets of the rheumatoid arthritis-
specific antifilaggrin autoantibodies are deiminated forms of the alpha-
and beta-chains of fibrin. J Immunol 2001, 166:4177-4184.
8. Vossenaar ER, Després N, Lapointe E, van der Heijden A, Lora M, Senshu T,
van Venrooij WJ, Ménard HA: Rheumatoid arthritis specific anti-Sa
antibodies target citrullinated vimentin. Arthritis Res Ther 2004, 6:
R142-R150.
9. Burkhardt H, Sehnert B, Bockermann R, Engstrom A, Kalden JR, Holmdahl R:
Humoral immune response to citrullinated collagen type II determinants
in early rheumatoid arthritis. Eur J Immunol 2005, 35:1643-1652.
10. Kinloch A, Tatzer V, Wait R, Peston D, Lundberg K, Donatien P, Moyes D,
Taylor PC, Venables PJ: Identification of citrullinated alpha-enolase as a
candidate autoantigen in rheumatoid arthritis. Arthritis Res Ther 2005, 7:
R1421-R1429.
11. Chang X, Yamada R, Suzuki A, Kochi Y, Sawada T, Yamamoto K:
Citrullination of fibronectin in rheumatoid arthritis synovial tissue.
Rheumatology 2005, 44:1374-1382.
12. Vossenaar ER, van Venrooij WJ: Citrullinated proteins: sparks that may
ignite the fire in rheumatoid arthritis. Arthritis Res Ther 2004, 6:107-111.
13. Srebrow A, Blaustein M, Kornblihtt AR: Regulation of fibronectin
alternative splicing by a basement membrane-like extracellular matrix.
FEBS Lett 2002, 514:285-289.
14. Walle TK, Vartio T, Helve T, Virtanen HI, Kurki R: Cellular fibronectin in
rheumatoid synovium and synovial fluid: a possible factor contributing
to lymphocytic infiltration. Scand J Immtmol 1990, 31:535-540.
15. Barilla ML, Carsons SE: Fibronectin fragments and their role in
inflammatory arthritis. Semin Arthritis Rheum 2000, 29:252-265.
16. Shiozawa K, Hino K, Shiozawa S: Alternatively spliced EDA-containing
fibronectin in synovial fluid as a predictor of rheumatoid joint
destruction. Rheumatology (Oxford) 2001, 40:739-472.
17. Luban S, Li ZG: Citrullinated peptide and its relevance to rheumatoid
arthritis: an update. Int J Rheum Dis 2010, 13:284-287.
18. Pruijn GJ, Wiik A, van Venrooij WJ: The use of citrullinated peptides and
proteins for the diagnosis of rheumatoid arthritis. Arthritis Res Ther 2010,
12:203.
19. Konttinen YT, Nykänen P, Nordström D, Saari H, Sandelin J, Santavirta S,
Kouri T: DNA synthesis in prolyl 4-hydroxylase positive fibroblasts in situ
in synovial tissue. An autoradiography-immunoperoxidase double
labeling study. J Rheumatol 1989, 16:339-345.
20. Mohr W, Hummler N, Pelster B, Wessinghage D: Proliferation of pannus
tissue cells in rheumatoid arthritis. Rheumatol Int 1986, 6:127-132.
21. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N:
Expression of survivin and its relationship to loss of apoptosis in breast
carcinomas. Clinical Cancer Research 2000, 6:127-134.
22. Blanc-Brude OP, Mesri M, Wall NR, Plescia J, Dohi T, Altieri DC: Therapeutic
targeting of the survivin pathway in cancer: initiation of mitochondrial
apoptosis and suppression of tumor-associated angiogenesis. Clin Cancer
Res 2003, 9:2683-2692.
23. Choy EH, Panayi GS: Cytokine pathways and joint inflammation in
rheumatoid arthritis. N Engl J Med 2001, 344:907-916.
24. Dayer JM: Interleukin 1 or tumor necrosis factor-alpha: which is the real
target in rheumatoid arthritis? J Rheumatol 2002, 65(Suppl):10-5.
25. Kotake S, Udagawa N, Hakoda M, Mogi M, Yano K, Tsuda E, Takahashi K,
Furuya T, Ishiyama S, Kim KJ, Saito S, Nishikawa T, Takahashi N, Togari A,
Tomatsu T, Suda T, Kamatani N: Activated human T cells directly induce
osteoclastogenesis from human monocytes: Possible role of T cells in
bone destruction in rheumatoid arthritis patients. Arthritis Rheum 2001,
44:1003-1012.
26. Takayanagi H, Iizuka H, Juji T, Nakagawa T, Yamamoto A, Miyazaki T,
Koshihara Y, Oda H, Nakamura K, Tanaka S: Involvement of receptor
activator of nuclear factor kappa B ligand/osteoclast differentiation
factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis.
Arthritis Rheum 2000, 43:259-269.
27. Skoumal M, Kolarz G, Haberhauer G, Woloszczuk W, Hawa G, Klingler A:
Osteoprotegerin and the receptor activator of NF-kappa B ligand in the
serum and synovial fluid. A comparison of patients with longstanding
rheumatoid arthritis and osteoarthritis. Rheumatol Int 2005, 26:63-69.
28. Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E, Goldring SR:
Synovial tissue in rheumatoid arthritis is a source of osteoclast
differentiation factor. Arthritis Rheum 2000, 43:250-258.
29. Page G, Miossec P: RANK and RANKL expression as markers of dendritic
cell-T cell interactions in paired samples of rheumatoid synovium and
lymph nodes. Arthritis Rheum 2005, 52:2307-2312.
30. Chang X, Yamada R, Suzuki A, Sawada T, Yoshino S, Tokuhiro S,
Yamamoto K: Localization of peptidylarginine deiminase 4 (PADI4) and
citrullinated protein in synovial tissue of rheumatoid arthritis.
Rheumatology 2005, 44:40-50.
31. Chang X, Zhao Y, Sun S, Zhang Y, Zhu Y: The expression of PADI4 in
synovium of rheumatoid arthritis. Rheumatol Int 2009, 29:1411-1416.
32. Fan LY, He DY, Wang Q, Zong M, Zhang H, Yang L, LS Sun LS: Citrullinated
vimentin stimulates proliferation, pro-inflammatory cytokine secretion,
and PADI4 and RANKL expression of fibroblast-like synoviocytes in
rheumatoid arthritis. Scand J Rheumatol 2012, 41:354-358.
doi:10.1186/ar4112
Cite this article as: Fan et al.: Citrullinated fibronectin inhibits apoptosis
and promotes the secretion of pro-inflammatory cytokines in fibroblast-
like synoviocytes in rheumatoid arthritis. Arthritis Research & Therapy 2012
14:R266.
Fan et al. Arthritis Research & Therapy 2012, 14:R266
http://arthritis-research.com/content/14/6/R266
Page 9 of 9
